1117-66-4

Usage

Uses

Used in Chemical Research and Development:
7-Amino-heptanoic acid HCl, 98.0+% is used as a building block for organic synthesis in chemical research and development. Its unique structure and properties make it a valuable component in the synthesis of various compounds.
Used in Pharmaceutical Industry:
7-Amino-heptanoic acid HCl, 98.0+% is used as a starting material or intermediate in the production of various pharmaceuticals and other bioactive compounds. Its versatility and reactivity in organic synthesis contribute to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
7-Amino-heptanoic acid HCl, 98.0+% is used as a key component in the synthesis of complex organic molecules. Its seven-carbon chain and amino group provide opportunities for further functionalization and modification, enabling the creation of a wide range of bioactive compounds.

InChI:InChI=1/C9H19NO2/c1-2-12-9(11)7-5-3-4-6-8-10/h2-8,10H2,1H3

Upstream product

• 502-44-3 hexahydro-2H-oxepin-2-one 
• 64-17-5 ethanol 
• 143-33-9 sodium cyanide 
• 76455-55-5 ethyl ζ-nitroheptanoate 
• 929-17-9 7-aminoheptanoic acid 
• 29823-18-5 ethyl 7-bromoheptanoate 
• 1313585-64-6 C₃₇H₄₀F₁₇NO₅ 
• 1313585-79-3 ethyl 7-(((4-(2-perfluoroctylethyl)benzyl)oxy)amino)heptanoate hydrochloride 
• 1313585-47-5 ethyl 7-(tert-butoxycarbonyl(4-(2-perfluoroctylethyl)benzyloxy)amino)heptanoate 
• 927831-56-9 ethyl 7-azidoheptanoate 
• 25542-62-5 6-bromo-hexanoic acid ethyl ester 
• 4224-70-8 6-bromohexanoic acid 
• 10137-65-2 ethyl 6-cyanohexanoate 

Downstream Products

• 1254178-08-9 C₅₂H₅₇N₇O₄ 
• 191172-75-5 tianeptine 
• 66981-77-9 ethyl 7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoate 

Relevant academic research and scientific papers

Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma

Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized. Among them, compounds 7e–7g showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously. They also displayed good growth inhibitory activities against human MM cell line RPMI-8226, which proved their potential value for the treatment of multiple myeloma.

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors

While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20–40% of patients have no response to these agents. It has been stipulated that the lack of response and the development of secondary resistance to these drugs may be due to the presence of AR splice variants. HDAC6 has a role in regulating the androgen receptor (AR) by modulating heat shock protein 90 (Hsp90) acetylation, which controls the nuclear localization and activation of the AR in androgen-dependent and independent scenarios. With dual-acting AR–HDAC6 inhibitors it should be possible to target patients who don't respond to enzalutamide. Herein, we describe the design, synthesis and biological evaluation of dual-acting compounds which target AR and are also specific towards HDAC6. Our efforts led to compound 10 which was found to have potent dual activity (HDAC6 IC50= 0.0356 μM and AR binding IC50= 0.03 μM). Compound 10 was further evaluated for antagonist and other cell-based activities, in vitro stability and pharmacokinetics.

Synthesis of N-alkylated amino acids using fluorous-tagged hydroxylamines

The development of a new fluorous-tagged ammonia-equivalent for the synthesis of N-alkylated amino acids is described. The required building blocks were readily accessed in high yield and purity using F-SPE purification technique. Coupling of the fluorous

Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation

Synthesis of novel amides and esters prodrugs of olmesartan is described. Their in vitro stability in rat plasma was tested. The results showed that the ester derivative IIa with n-octyl substituted dioxolone moiety was rapidly converted into olmesartan within 30 min. The pharmacokinetic parameters of IIa were studied and compared with those of olmesartan medoxomil. Compound IIa is proposed to be a promising prodrug of olmesartan.

SULFONAMIDES

The present invention provides R, R1, R2, R3, X, c, d, e, f, g, x, y, a, b, z and n are defined in the specification. These compounds are useful in lowering IOP and/or treating glaucoma or providing neuroprotection to the

Aminomethylation of functionalized organozinc reagents and grignard reagents using immonium trifluoroacetates

New immonium trifluoroacetates 1 and 2 react readily with functionalized organozinc or magnesium reagents leading to the corresponding aminomethylated products of type 5 and 7. The resulting bis-allylamines were deallylated leading to primary amines.

Reduction of Aliphatic and Aromatic Nitro Compounds with Sodium Borohydride in Tetrahydrofuran Using 10percent Palladium-on-Carbon as Catalyst

Aliphatic and aromatic nitro compounds are reduced to amino compounds in good yields with sodium borohydride in tetrahydrofuran using 10percent palladium-on-carbon as catalyst.